Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775369 | 0.72 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL182469 | 0.67 | — | — | |
| SCHEMBL1243018 | 0.67 | TSHR (0.42) | TSHRALDH1A1 | |
| SCHEMBL1449926 | 0.65 | — | — | |
| SCHEMBL15011668 | 0.65 | MAPT (0.39) | TSHRALDH1A1 | |
| SCHEMBL10581677 | 0.65 | TSHR (0.33) | TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL6271378 | 0.65 | — | — | |
| SCHEMBL5686826 | 0.65 | — | — | |
| SCHEMBL7141375 | 0.65 | — | — | |
| SCHEMBL23732 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873671-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170015629-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-01-19 | — | — | US | disclosed |
| US-7344818-B2 | Method for producing toner and an image forming method employing the toner | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20050014084-A1 | Method for producing toner and an image forming method employing the toner | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015629-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | TSHR 3422/4885ALDH1A1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.